Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan News Release    20170901

By JPN, Pharmaceutical

Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan News Release

http://www.ono.co.jp/eng/news/pdf/sm_cn170901.pdf

More from tokioX :

  1. 💊Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma
  2. 💊Ono Enters into Exclusive License Agreement with Karyopharm to Develop and Commercialize Selinexor and KPT-8602, XPO1 Inhibitors  20171012
  3. 👾Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan News Release
  4. Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea  20170919
  5. ono、Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
  6. Two important clinical trials of Ono Pharmaceuticals, Opivo® (generic name: niborumab) demonstrate the benefits of three-year survival in patients   20170911
  7. CONCLUSION OF DEVELOPMENT COLLABORATION AGREEMENT FOR OPDIVO® (NIVOLUMAB) AND LENVIMA® (LENVATINIB MESYLATE) COMBINATION THERAPY FOR TREATMENT OF HEPATOCELLULAR CARCINOMA 20170908